Pharmaceutical Analytical Chemistry: Open Access
Open Access

Energy Metabolism of PEGylated and Fluorinated Chitosans: Advancements in Targeted Particle Synthesis for Drug Delivery

Vinit Raj^{* *}Correspondence: Vinit Raj, Department of Pharmaceutical Chemistry, University of Chitkara, Punjab, India, Email:

Author info »

Description

Recent advancements in polymer science have led to the development of novel biomaterials for drug delivery applications. Among these, PEGylated and fluorinated chitosan’s have garnered significant attention due to their unique properties that enhance biocompatibility, stability, and targeted drug delivery capabilities. This article explores the energy metabolism characteristics of PEGylated and fluorinated chitosan’s and their application in the synthesis of targeted particles for efficient drug delivery [1].

Chitosans: A versatile biomaterial

Chitosan, derived from chitin, is a biocompatible and biodegradable polysaccharide widely studied for biomedical applications. Its chemical modification through PEGylation (Polyethylene Glycol Conjugation) and fluorination enhances its properties, making it suitable for controlled drug release systems and targeted delivery to specific tissues or cells.

Energy metabolism insights: Understanding the energy metabolism of PEGylated and fluorinated chitosan’s is important for optimizing their use in drug delivery systems:

PEGylation: Attachment of Polyethylene Glycol (PEG) chains to chitosan alters its surface properties, reducing immunogenicity and prolonging circulation time by evading immune system recognition.

Fluorination: Introduction of fluorine atoms enhances hydrophobicity and stability, improving the structural integrity of chitosan-based nanoparticles and their interactions with biological membranes [2]. The synthesis of targeted particles for drug delivery involves several key steps:

Nanoparticle formulation: PEGylated and fluorinated chitosan’s can self-assemble or be formulated into nanoparticles through techniques such as nanoprecipitation, emulsion methods, or electrostatic complexation with drugs or therapeutic agents.

Surface modification: Functionalization of nanoparticle surfaces with ligands (e.g., antibodies, peptides) allows for specific targeting of diseased tissues or cells, minimizing off-target effects and enhancing therapeutic efficacy [3].

Controlled release systems: Incorporation of drugs within PEGylated or fluorinated chitosan nanoparticles enables controlled release kinetics, ensuring sustained therapeutic concentrations at the target site while reducing systemic toxicity.

Advantages in drug delivery

PEGylated and fluorinated chitosan nanoparticles offer several advantages for drug delivery applications:

Enhanced biocompatibility: Reduced immunogenicity and improved stability in biological fluids enhance biocompatibility and safety profiles.

Targeted delivery: Surface modifications facilitate specific binding to receptors overexpressed on diseased cells or tissues, enhancing drug accumulation at the target site.

Controlled release: Precise control over drug release kinetics prolongs therapeutic efficacy and minimizes frequent dosing, improving patient compliance [4].

Biomedical applications

The application of PEGylated and fluorinated chitosan nanoparticles spans various biomedical fields:

Cancer therapy: Targeted delivery of chemotherapeutic agents reduces systemic side effects and improves tumor accumulation, enhancing therapeutic outcomes.

Infectious diseases: Antimicrobial drugs delivered via chitosan nanoparticles exhibit enhanced efficacy against resistant pathogens and biofilms.

Regenerative medicine: Growth factors and biomolecules delivered using chitosan nanoparticles promote tissue repair and regeneration in wound healing and tissue engineering applications [5].

Challenges and considerations

Despite the potential of PEGylated and fluorinated chitosan’s in drug delivery, challenges remain:

Biodegradability: Ensuring controlled degradation and elimination of nanoparticles to minimize long-term accumulation and potential toxicity.

Scale-up and manufacturing: Transitioning from laboratory- scale synthesis to commercial production while maintaining nanoparticle integrity and consistency.

Clinical translation: Addressing regulatory requirements and conducting rigorous preclinical [6].

Future research directions focus on

Multifunctional nanoparticles: Designing nanoparticles with combined functionalities (e.g., imaging, therapy, targeting) to enhance diagnostic and therapeutic outcomes.

Personalized medicine: Tailoring nanoparticle formulations for individualized treatment strategies based on patient-specific characteristics and disease profiles.

Integration of emerging technologies: Incorporating advances in nanotechnology, biomaterials, and drug delivery systems to innovate and improve therapeutic interventions [7].

Conclusion

In conclusion, PEGylated and fluorinated chitosan’s represent versatile platforms for the synthesis of targeted particles in drug delivery applications. Their unique energy metabolism profiles and surface modifications enable precise control over drug release and targeting, advancing personalized medicine and improving therapeutic outcomes across various disease conditions. Continued research and development efforts are optimistic to harnessing the full potential of these biomaterials, ensuring their safe and effective translation from bench to bedside in clinical settings.

References

1. Li SM, Chou JY, Tsai SE, Tseng CC, Chung CY, Zeng WZ, et al. Synthesis and anti-inflammatory activity evaluation of NO-releasing furoxan/1, 2, 4-triazole hybrid derivatives. Eur J Med Chem. 2023;257 :115496.

   [Crossref] [Google Scholar] [PubMed]

2. Wang Y, Ding Y, Wang C, Gao M, Xu Y, Ma X, et al. Fenretinide-polyethylene glycol (PEG) conjugate with improved solubility enhanced cytotoxicity to cancer cell and potent in vivo efficacy. Pharm Dev Technol. 2020;25(8):962-970.

   [Crossref] [Google Scholar] [PubMed]

3. Abdelmalek MF, Charles ED, Sanyal AJ, Harrison SA, Neuschwander-Tetri BA, Goodman Z, et al. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials. 2021; 104:106335.

   [Crossref] [Google Scholar] [PubMed]

4. Gallego-Escuredo JM, Lamarca MK, Villarroya J, Domingo JC, Mateo MG, del Mar Gutierrez M, et al. High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients. Metabolism. 2017; 71:163-170. 

   [Crossref] [Google Scholar] [PubMed]

5. Brun E, Sicard-Roselli C. Actual questions raised by nanoparticle radiosensitization. Radiat. Phys. Chem. 2016; 128:134-142.

   [Crossref] [Google Scholar]

6. Conde J, Doria G, Baptista P. Noble metal nanoparticles applications in cancer. J Drug Deliv. 2012;2012(1):751075.

   [Crossref] [Google Scholar] [PubMed]

7. Sánchez-López E, Ettcheto M, Egea MA, Espina M, Calpena AC, Folch J, et al. New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. Nanomedicine. 2017;13(3):1171-1182.

   [Crossref] [Google Scholar] [PubMed]